Key facts
- This page summarizes Cameron Durrant's Form 4 filing for HUMANIGEN, INC.
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 Jul 2022, 18:30.
Cameron Durrant - 27 Jul 2022 Form 4 Insider Report for HUMANIGEN, INC
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 27 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Jul 2022, 18:30:24 UTC
- Prior SEC filing
- 04 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Henry Madrid, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Cameron Durrant filed Form 4 for HUMANIGEN, INC on 29 Jul 2022.
Change
- Previous filing in this sequence was filed on 04 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HGEN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +808,906
- Change %
- Price
- $0.000000
- Shares after
- 808,906
- Date
- 27 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 808,906
- Exercise price
- $0.3800
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests in two equal installments on the first and second anniversaries of the grant date.